Elite Journal of Medical Sciences. Volume 1 issue 1(2023), Pp. 14-24
https://epjournals.com/journals/EJMS

Immunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay

[*]Emmanuel Ifeanyi Obeagu[1]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) represents a hematologic disorder characterized by bone marrow failure, leading to peripheral blood pancytopenia. While its etiology remains multifaceted, the intersection of immunological factors, particularly in the presence of HIV infection, poses intriguing challenges and opportunities for elucidating its pathogenesis. This review synthesizes current understanding regarding the immunological facets of aplastic anemia within the context of HIV, exploring the intricate interplay between immune dysregulation, viral pathogenesis, and hematopoietic suppression. Immunological perturbations associated with HIV infection exacerbate bone marrow dysfunction through T-cell mediated mechanisms and dysregulated cytokine signaling, amplifying immune-mediated marrow destruction. Therapeutic approaches targeting both immunological dysregulation and viral suppression offer promise in managing aplastic anemia in HIV-infected individuals. Understanding the immunopathogenesis of this complex interplay provides insights into novel therapeutic strategies aimed at restoring hematopoietic function and improving clinical outcomes.

Keywords: *Immunology, Aplastic Anemia, HIV, Immune Dysregulation, Hematopoiesis, Immunosuppression*

Introduction

Aplastic anemia (AA) stands as a formidable hematologic challenge, characterized by the failure of bone marrow to produce an adequate number of blood cells, resulting in peripheral blood pancytopenia. Despite its rarity, its clinical impact is profound, necessitating a comprehensive understanding of its pathogenesis for effective management. While AA can arise from various etiologies, ranging from idiopathic to drug-induced, the intersection with immunological factors

has emerged as a pivotal area of investigation. Particularly intriguing is the interplay between immune dysregulation and hematopoietic suppression, a dynamic further complicated in the context of HIV infection. T-cell mediated mechanisms, characterized by cytotoxic CD8+ T cells, have been implicated in the pathogenesis of AA, perpetuating an immune assault on HSCs. Moreover, dysregulated cytokine signaling, notably elevated levels of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), further exacerbate marrow destruction, amplifying the immune-mediated component of AA. HIV infection, renowned for its profound impact on the immune system, introduces a layer of complexity to the understanding of AA. Chronic immune activation, CD4+ T-cell depletion, and dysregulated cytokine production hallmark HIV infection, creating a milieu ripe for hematopoietic suppression. HIV-associated immunological perturbations not only exacerbate the immune-mediated destruction of HSCs but also disrupt the delicate balance of hematopoietic niches, fostering an environment conducive to the development of AA.[1-15]

The coexistence of HIV and AA presents clinicians with a unique set of challenges, necessitating a nuanced understanding of their intertwined immunopathogenesis. The loss of immune regulatory mechanisms, such as regulatory T cells (Tregs), further exacerbates the immunological dysregulation observed in both conditions. Moreover, the direct effects of HIV on HSCs and hematopoietic progenitor cells contribute to the pathogenesis of AA, highlighting the complex interplay between viral infection and immune-mediated bone marrow suppression. Therapeutic strategies targeting the immunological dysregulation in AA within the context of HIV infection represent a frontier in clinical management. While hematopoietic stem cell transplantation (HSCT) remains the gold standard for eligible patients, challenges such as donor availability and post-transplant complications persist. Immunomodulatory agents, including anti-thymocyte globulin (ATG) and cyclosporine, offer alternative avenues to mitigate immune-mediated marrow destruction and improve clinical outcomes. Understanding the immunopathogenesis of AA in the setting of HIV infection provides a foundation for the development of targeted therapeutic interventions aimed at restoring hematopoietic function and ameliorating clinical sequelae in affected individuals.[16-25]

Immunopathogenesis of Aplastic Anemia

The immunopathogenesis of aplastic anemia (AA) unveils a complex interplay between the immune system and hematopoietic stem cell (HSC) homeostasis. In AA, aberrant immune responses target HSCs within the bone marrow, resulting in their destruction and subsequent pancytopenia. Central to this process are cytotoxic T lymphocytes (CTLs), particularly CD8+ T cells, which recognize HSC antigens and initiate a cascade of immune-mediated cytotoxicity. Studies have identified an expansion of activated CTL populations in the bone marrow of AA patients, underscoring their pivotal role in mediating HSC destruction. Moreover, dysregulation of cytokine signaling further exacerbates the immunopathogenesis of AA. Elevated levels of pro-inflammatory cytokines, notably interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), have been implicated in promoting HSC apoptosis and inhibiting hematopoietic progenitor cell proliferation. These cytokines not only perpetuate the inflammatory milieu within the bone marrow but also disrupt the delicate balance of hematopoietic niches, impeding the regenerative capacity of the marrow.[26-30]

The pathogenic mechanisms driving immune dysregulation in AA remain multifactorial, with contributions from both innate and adaptive immune components. In addition to CTL-mediated cytotoxicity, dysregulated immune checkpoints, such as the programmed cell death protein 1 (PD-1) pathway, play a critical role in perpetuating immune-mediated marrow destruction. PD-1, expressed on activated T cells, interacts with its ligands PD-L1 and PD-L2 on target cells, including HSCs, leading to T cell exhaustion and impaired immune regulation. Furthermore, the loss of immune regulatory mechanisms, such as regulatory T cells (Tregs), exacerbates the immunopathogenesis of AA. Tregs, characterized by their ability to suppress effector T cell responses, play a crucial role in maintaining immune tolerance and preventing autoimmunity. Deficiencies in Treg function or numbers have been observed in AA patients, further perpetuating the dysregulated immune response against HSCs. The immunopathogenesis of AA is also influenced by environmental factors, including exposure to toxins and infectious agents. Viral infections, such as hepatitis viruses and parvovirus B19, have been implicated in triggering immune-mediated bone marrow suppression, further highlighting the intricate interplay between infectious triggers and dysregulated immune responses in AA.[30-40]

HIV-Associated Immunological Perturbations

HIV infection instigates a myriad of immunological perturbations that profoundly impact both innate and adaptive immune responses. Central to HIV pathogenesis is the progressive depletion of CD4+ T lymphocytes, the key orchestrators of adaptive immunity. This depletion not only impairs host defense against opportunistic infections but also disrupts the delicate balance of immune regulation, fostering a state of chronic immune activation. The dysregulation of immune checkpoints, such as the programmed cell death protein 1 (PD-1) pathway, further exacerbates immune dysfunction by promoting T cell exhaustion and impairing immune surveillance. Chronic immune activation, a hallmark of HIV infection, manifests through the persistent production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These cytokines not only fuel systemic inflammation but also contribute to the pathogenesis of HIV-associated comorbidities, including cardiovascular disease and neurocognitive disorders. Additionally, dysregulated cytokine signaling disrupts hematopoietic niches within the bone marrow, impairing hematopoietic stem cell (HSC) function and contributing to the development of bone marrow suppression.[41-50]

The loss of immune regulatory mechanisms further amplifies the immunological perturbations observed in HIV infection. Regulatory T cells (Tregs), crucial mediators of immune tolerance and homeostasis, are depleted and functionally impaired in HIV-infected individuals. This depletion of Tregs unleashes unchecked immune activation and inflammation, exacerbating tissue damage and contributing to the pathogenesis of HIV-associated autoimmune and inflammatory diseases. Moreover, the dysregulation of innate immune responses plays a pivotal role in driving HIV-associated immunopathogenesis. Persistent activation of innate immune cells, including monocytes and dendritic cells, fuels chronic inflammation and contributes to tissue damage and dysfunction. Dysfunctional antigen-presenting cells impair the induction of effective adaptive immune responses, further compromising host defense against opportunistic infections and malignancies. The complex interplay between HIV-associated immunological perturbations and

hematopoietic suppression is underscored by the development of aplastic anemia (AA) in HIV-infected individuals. HIV-induced immune dysregulation disrupts the delicate balance of hematopoietic niches, fostering an environment conducive to the development of AA. Moreover, direct viral effects on HSCs and dysregulated cytokine signaling exacerbate immune-mediated marrow destruction, further complicating the management of AA in the setting of HIV infection.[51-75]

Conclusion

The intersection of immunological aspects with aplastic anemia (AA) within the setting of HIV infection presents a complex and multifaceted challenge. AA, characterized by bone marrow failure and peripheral blood pancytopenia, involves a delicate balance between immune regulation and hematopoietic homeostasis. Immunological dysregulation, mediated by aberrant immune responses targeting hematopoietic stem cells (HSCs) and dysregulated cytokine signaling, plays a central role in the pathogenesis of AA. In the context of HIV infection, profound immunological perturbations further exacerbate the immune dysregulation observed in AA. HIV-induced CD4+ T cell depletion, chronic immune activation, and dysregulated cytokine production create an inflammatory milieu that disrupts hematopoietic niches and impairs HSC function. The loss of immune regulatory mechanisms, such as regulatory T cells (Tregs), amplifies immune activation and inflammation, contributing to the pathogenesis of both HIV-associated complications and AA.

References

1. Sankar V, Villa A. Hematologic diseases. Burket's Oral Medicine. 2021:627-664.
2. Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. American journal of clinical pathology. 2013;139(1):9-29.
3. Smith JN, Kanwar VS, MacNamara KC. Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. Frontiers in Immunology. 2016; 7:217479.
4. Storb RF, Lucarelli G, McSweeney PA, Childs RW. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. ASH Education Program Book. 2003;2003(1):372-397.
5. Volberding PA, Baker KR, Levine AM. Human immunodeficiency virus hematology. ASH Education Program Book. ;2003(1):294-313.
6. Blood GA. Human immunodeficiency virus (HIV). Transfusion Medicine and Hemotherapy. 2016;43(3):203.
7. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A, Alexander H, Hurlston Cox M, Nkengasong JN. Diagnosis of human immunodeficiency virus infection. Clinical microbiology reviews. 2018;32(1):10-128.
8. Opie J. Haematological complications of HIV infection: forum-review. South African Medical Journal. 2012;102(6):465-468.
9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.

10. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
11. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
12. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
13. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
14. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
15. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
16. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
18. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
19. Gandhi S, Abuarqoub H, Kordasti S, Jiang J, Kulasekararaj A, Mufti G, Marsh JC. Pathology of bone marrow failure syndromes. Diagnostic Histopathology. 2015;21(5):174-180.
20. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
21. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS

victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009

22. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
23. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
24. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
25. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
26. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
27. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
28. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
29. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
30. Bonadies N, Rovó A, Porret N, Bacher U. When should we think of myelodysplasia or bone marrow failure in a thrombocytopenic patient? A practical approach to diagnosis. Journal of clinical medicine. 2021;10(5):1026.

31. Groarke EM, Young NS, Calvo KR. Distinguishing constitutional from acquired bone marrow failure in the hematology clinic. Best Practice & Research Clinical Haematology. 2021;34(2):101275.
32. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
33. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
34. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
35. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
36. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun

Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.

41. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
42. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
44. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
45. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
46. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
47. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
48. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
49. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.

50. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
51. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
52. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
53. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
54. Wilson CS, Brynes RK. Evaluation of anemia, leukopenia, and thrombocytopenia. Hematopathology E-Book. 2010:154.
55. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Advances. 2021;5(12):2660-2671.
56. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
57. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
58. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
59. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
60. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
61. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
62. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.

63. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
64. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
65. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
66. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
67. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
68. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
69. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
70. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
71. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
72. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
73. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, The Journal of the American Society of Hematology. 2022;140(12):1345-1377.
74. Acevedo A, Alférez S, Merino A, Puigví L, Rodellar J. Automatic recognition system of nucleated peripheral blood cell images. Int. J. Lab. Hematol. 2016; 38:1-.
75. Yusuf AA, Musa BM, Galadanci NA, Babashani M, Mohammed AZ, Ingles DJ, Fogo AB, Wester CW, Aliyu MH. HIV-associated nephropathy: Protocol and rationale for an exploratory genotype-phenotype study in a sub-Saharan African population. Plos one. 2021;16(4):e0249567.